VP11-2021: Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study

T. André, A Falcone, Y. Shparyk, F. V. Moiseenko, E. Polo Marques, T. Csoszi, A. Campos Bragagnoli, Gabor Liposits, E. Chmielowska, P. Aubel, L. Martín-Fernández, R. Fougeray, N. Causse-Amellal, Mark P Saunders

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
Article numberVP11-2021
JournalAnnals of Oncology
Volume33
Issue number2
Pages (from-to)229-230
ISSN0923-7534
DOIs
Publication statusPublished - Feb 2022
Externally publishedYes
EventESMO Immuno-Oncology Congress 2021 -
Duration: 8. Dec 202111. Dec 2021

Conference

ConferenceESMO Immuno-Oncology Congress 2021
Period08/12/202111/12/2021

Cite this